KRAS G12D Mutation Clinical Trials in Shanghai
2 recruitingShanghai, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Pancreatic Ductal Adenocarcinoma (PDAC)KRAS G12D Mutations
Ranok Therapeutics (Hangzhou) Co., Ltd.60 enrolled2 locationsNCT07303465
Recruiting
Phase 1Phase 2
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd.152 enrolled6 locationsNCT06667544